Cerebrolysin Reference

Plain English

What it is

Cerebrolysin is a mixture of small protein pieces (peptides) and amino acids made from purified pig brain tissue. It is not approved by the US Food and Drug Administration. It is approved in several other countries, including parts of Europe, Asia, and the former Soviet states, for stroke, brain injury, and dementia.

What people use it for

In countries where it is approved, doctors give it through a vein or a muscle to help recovery after a stroke, a traumatic brain injury, or dementia. Some people in the wider community try it hoping for a brain or memory boost, which goes beyond what the studies actually tested.

What the science shows

Most of the human trials looked at recovery soon after an ischemic stroke, which is a stroke caused by a blocked blood vessel. Reviews that pool many trials report mixed but generally positive results for short-term neurological recovery, though the quality of the studies is debated and the benefit for everyday independence is still unclear. It has not been shown to boost memory or thinking over the long term in healthy people.

The catch

It is made from animal (pig) brain tissue, so there is a risk of contamination, and any injection carries some risk. It is not FDA-approved, no proven community plan exists, and the long-term brain-boost use that some people seek is not backed by the trials.

Reference summary

Published randomized human trial literature exists primarily in acute ischemic stroke and vascular dementia, with meta-analyses reporting mixed but generally positive effect sizes. Trial quality and generalizability beyond acute-stroke settings remain debated.

Regulatory and posture

Categories

Cognitive, Longevity

Aliases

Porcine-brain peptide mixture, FPF-1070

Evidence posture

translational - Approved in several non-US markets but not FDA-approved. Trial quality and generalizability beyond acute-stroke settings are debated; long-term cognitive-enhancement use is not supported by the trial base. No validated subcutaneous community protocol exists.

Regulatory status

No FDA-approved Cerebrolysin drug label. Cerebrolysin is a porcine-brain-derived neuropeptide mixture approved in several non-US markets (including parts of Europe, Asia, and the former Soviet states) for stroke, traumatic brain injury, and dementia indications; it is not FDA-approved.

Content review status

research reference

Related tools

• Injection-site rotation overview - Public overview of the Pro site-rotation planner.
• Protocol builder overview - Public overview of the Pro protocol builder.